Welcome to our dedicated page for Ocular Therapeut SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ocular Therapeutix, Inc. (NASDAQ: OCUL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including 8-K current reports and other documents filed with the U.S. Securities and Exchange Commission. These filings give detailed insight into Ocular Therapeutix’s clinical programs, financing activities, and key corporate events as it advances ophthalmic therapies based on its ELUTYX bioresorbable hydrogel technology.
Recent 8-K filings describe the structure and status of the AXPAXLI (OTX-TKI) registrational trials in wet age-related macular degeneration (wet AMD), including the SOL-1 and SOL-R Phase 3 studies, as well as plans for the SOL-X long-term extension trial. They also outline the design of the HELIOS-2 and HELIOS-3 Phase 3 trials in non-proliferative diabetic retinopathy (NPDR), the use of a novel ordinal diabetic retinopathy severity score (DRSS) endpoint, and Special Protocol Assessment (SPA) agreements with the FDA.
Other filings cover capital markets transactions, such as the September 30, 2025 underwriting agreement for a large common stock offering, expected net proceeds, and the company’s view of its cash runway into future years. Additional 8-Ks furnish quarterly financial results press releases, describe inducement equity awards under Nasdaq Listing Rule 5635(c)(4), and discuss notices of allowance from the U.S. Patent and Trademark Office related to AXPAXLI methods of use.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and can be paired with AI-powered summaries that explain the key points of lengthy documents like 8-Ks or registration statements in plain language. Users can quickly see how Ocular Therapeutix reports on trial designs, primary endpoints, regulatory interactions, cash resources, and potential patent protection. For investors tracking OCUL, this page is a central place to review official disclosures about clinical progress, financing arrangements, and other material events that may influence the company’s ophthalmology-focused pipeline and commercial product DEXTENZA.
Ocular Therapeutix shareholder files notice to sell shares under SEC Rule 144. The filing covers up to 10,348 shares of common stock, with an aggregate market value of $93,560.41, to be sold through Morgan Stanley Smith Barney on NASDAQ.
The shares were acquired on February 11, 2026 through restricted stock vesting under a registered plan. The notice also reports a prior sale over the last three months of 1,878 common shares for gross proceeds of $22,616.19.
A shareholder of OCUL has filed a notice of proposed sale under Rule 144 for 7,863 shares of common stock. The shares have an aggregate market value of $71,082.31 and are intended to be sold on NASDAQ around 02/12/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services.
The securities were acquired on 02/11/2026 as restricted stock vesting under a registered plan from the issuer, in the same amount of 7,863 shares, with no separate cash payment listed.
Deep Track Capital and affiliates report a significant ownership stake in Ocular Therapeutix, Inc. They beneficially own 11,234,132 shares of common stock, representing 5.13% of the company as of February 10, 2026.
The position is held through Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and individual reporting person David Kroin, who share dispositive power over the same 11,234,132 shares. This amount includes 1,163,718 pre-funded warrants that are exercisable into common stock, subject to a 9.99% “Maximum Percentage” limitation on beneficial ownership after exercise.
The ownership percentage is calculated using 218,855,497 shares, combining 217,691,779 shares outstanding as of February 2, 2026 and the shares underlying the pre-funded warrants. The filers certify that the securities are not held for the purpose of changing or influencing control of Ocular Therapeutix.
Ocular Therapeutix, Inc. has a new large shareholder disclosure from Deep Track Capital and affiliates. As of December 31, 2025, they report beneficial ownership of 9,234,132 shares of common stock, representing 4.31% of the company.
The position includes 1,163,718 pre-funded warrants that are exercisable into common shares but are subject to a 9.99% “Maximum Percentage” cap, meaning exercises cannot push the holder’s beneficial ownership above 9.99% of shares outstanding after exercise. The reporting persons certify the holdings are not for the purpose of changing or influencing control of the company.
Ocular Therapeutix details its strategy as an integrated biopharmaceutical company focused on retinal and other ophthalmic diseases using its ELUTYX hydrogel drug-delivery platform.
The lead asset AXPAXLI (OTX-TKI) is in Phase 3 registrational programs for wet age-related macular degeneration and diabetic retinal disease, targeting long-acting intravitreal therapy with 6–12 month dosing and potential NDA submission based primarily on the SOL-1 trial. The HELIOS program extends AXPAXLI into diabetic retinopathy using a novel ordinal DRSS endpoint.
Commercially, Ocular markets DEXTENZA, an FDA-approved dexamethasone intracanalicular insert for post-surgical ocular inflammation and pain and for ocular itching from allergic conjunctivitis, including pediatric use. The company is also evaluating next steps for glaucoma candidate OTX-TIC after completing Phase 2, and leverages partnerships with AffaMed in selected Asian markets.
Ocular Therapeutix, Inc. reported that it has released its financial results for the quarter and year ended December 31, 2025. These results were announced in a press release dated February 5, 2026.
The company furnished the full text of this earnings press release as Exhibit 99.1. This information is provided under a disclosure rule for earnings results and is designated as “furnished,” meaning it is not treated as formally “filed” under certain securities law liability provisions or automatically incorporated into other securities filings unless specifically referenced.
Ocular Therapeutix Chief Operating Officer Donald Notman reported two small sales of company common stock that were automatically executed to cover taxes on vested equity awards. On February 2, 2026, he sold 5,455 shares at a weighted average price of $9.14, tied to restricted stock units that vested January 30, 2026. On February 4, 2026, he sold 6,035 shares at a weighted average price of $8.54, related to restricted stock units that vested February 3, 2026. Both transactions were carried out under a durable automatic sales instruction letter dated May 13, 2022, and are described as non-discretionary sell-to-cover trades for tax withholding. After these transactions, Notman directly beneficially owned 377,802 shares of Ocular Therapeutix common stock.
Form 144 shows that Steve Meyers has filed a notice of intent to sell 4,408 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an approximate aggregate market value of $37,636.39. The issuer has 213,047,472 shares outstanding.
The shares to be sold come from restricted stock vesting under a registered plan on 02/03/2026, acquired directly from the issuer. In the prior three months, Meyers sold 3,052 common shares for $27,903.83. The filer represents they know no undisclosed material adverse information.
Ocular Therapeutix shareholder Donald D Notman Jr has filed a Form 144 notice to sell up to 6,035 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ around February 4, 2026. These 6,035 shares were acquired on February 3, 2026 through restricted stock vesting under a registered plan. The notice states that there were 213,047,472 common shares outstanding. The filing also reports that Notman previously sold 5,455 common shares on February 2, 2026 for gross proceeds of $49,872.88.
An affiliate of OCUL has filed a Rule 144 notice to sell 5,455 shares of the issuer’s common stock through Morgan Stanley Smith Barney LLC on the NASDAQ market. The shares have an indicated aggregate market value of $49,872.88 and were acquired on 01/30/2026 via restricted stock vesting under a registered plan. Common shares outstanding were 213,047,472 as of the filing, providing context for the planned sale size.